# US 2010/0168388 A1 · Stabilized p53 peptides and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168388 A1
- Document ID: US20100168388A1
- Status: Published application
- Kind: A1
- Application number: 12/525,123
- Filed: 2008-01-31
- Published: 2010-07-01
- Earliest claimed: 2007-01-31
- Assignees: Dana-Farber Cancer Institute, Inc.; President and Fellows of Harvard College
- Inventors: Federico Bernal; Loren D. Walensky; Gregory L. Verdine; Stanley J. Korsmeyer; Susan Korsmeyer
- Web page: https://patentgrep.com/patent/US20100168388A1

## CPC

- C07K 14/4746: {p53}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- C07K 1/113: without change of the primary structure
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Cross-linked peptides related to human p53 and bind to HMD2 or a family member of HDM2 useful for promoting apoptosis, e.g., in the treatment of and identifying therapeutic agents that binding to HMD2 or a family member of HDM2.

## Claims

### Claim 1

A modified polypeptide of Formula (I),
or a pharmaceutically acceptable salt thereof,
wherein:
each R1 and R2 are independently H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;
each R3 is independently alkyl, alkenyl, alkynyl; [R4—K—R4′]n; each of which is substituted with 0-6 R5;
R4 and R4′ are independently alkylene, alkenylene or alkynylene;
each R5 is independently is halo, alkyl, OR6, N(R6)2, SR6, SORB, SO2R6, CO2R6, R6, a fluorescent moiety, or a radioisotope;
K is independently O, S, SO, SO2, CO, CO2, CONR6 or
each R6 is independently H, alkyl, or a therapeutic agent;
n is an integer from 1-4;
x is 2, 3, 4 or 6;
y and w are independently integers from 0-100;
z is an integer from 1-10; and
each Xaa is independently an amino acid;
wherein the modified polypeptide comprises at least 8 contiguous amino acids of human p53 or a variant thereof or a homologue of human p53 or a variant thereof except that: (a) within the 8 contiguous amino acids the side chains of at least one pair of amino acids separated by 3, 4 or 6 amino acids is replaced by the linking group R3 which connects the alpha carbons of the pair of amino acids as depicted in Formula I and (b) the alpha carbon of the first amino acid of the pair of amino acids is substituted with R1 as depicted in formula I and the alpha carbon of the second amino acid of the pair of amino acids is substituted with R2 as depicted in Formula I.

### Claim 2 (depends on 1)

The modified polypeptide of claim 1, wherein the human p53 polypeptide comprises SEQ ID NO:1.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The modified polypeptide of claim 1, wherein the at least 8 contiguous amino acids of human p53 comprise at least 8 contiguous amino acids of:
(a) Xaa1Ser2Gln3Xaa4Thr5Phe6Xaa7Xaa8Leu9Trp10Xaa11Leu12Leu13Xaa14Xaa15Asn16 (SEQ ID NO:3), wherein each of Xaa1, Xaa4, Xaa7, Xaa8, Xaa11, Xaa14, Xaa15 are any amino acid or; (b) Gln1Ser2Gln2Gln4Thr5Phe6Ser7Asn8Leu9Trp10Arg11Leu12Leu13Pro14Gln15Asn16 (SEQ ID NO:6 wherein none or up to 6 amino acids other than Phe6, Trp10 and Leu13 are independently replaced by any other amino acid.

### Claim 5 (depends on 1)

The modified polypeptide of claim 1, wherein the modified polypeptide binds to HDM2.

### Claim 6 (depends on 1)

The modified polypeptide of claim 1, wherein x is 2.

### Claim 7 (depends on 1)

The modified polypeptide of claim 1, wherein x is 3.

### Claim 8 (depends on 1)

The modified polypeptide of claim 1, wherein x is 6.

### Claim 9 (depends on 1)

The modified polypeptide of claim 1, wherein x is 2, 3 or 6; R3 is an alkenyl containing a single double bond, and both R1 and R2 are H.

### Claim 10 (depends on 1)

The modified polypeptide of claim 1, wherein each y is independently an integer between 3 and 15.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13 (depends on 4)

The modified polypeptide of claim 4 wherein the at least 8 contiguous amino acids of human p53 comprise at least 8 continuous amino acids of Gln1Ser2Gln3Gln4Thr5Phe6Ser1Asn8Leu9Trp10Arg11Leu10Leu13Pro14Gln Asn16(SEQ ID NO:6) wherein Leu1 and Lys11 are both independently replaced by any other amino acid.

### Claim 14

(canceled)

### Claim 15 (depends on 13)

The modified polypeptide of claim 13 wherein Glu4 is replaced by any amino acid other than Asp.

### Claim 16 (depends on 13)

The modified polypeptide of claim 13 wherein Asp8 is replaced by any amino acid other than Glu.

### Claim 17 (depends on 13)

The modified polypeptide of claim 13 wherein the polypeptide does not have a net negative charge at pH 7.

### Claim 18 (depends on 17)

The modified polypeptide of claim 17 wherein the polypeptide comprises at least one amino acid that has a positive charge at pH 7 either: (a) amino terminal to Leu1 or the amino acid substituted for Leu1 or (b) carboxy terminal to Asn16 or the amino acid substituted for Asn16.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

The modified polypeptide of claim 1, wherein R1 and R2 are each independently H or C1-C6 alkyl.

### Claim at position 21

21-24. (canceled)

### Claim 25 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is C8 alkyl.

### Claim 26 (depends on 1)

The modified polypeptide of claim 1, wherein x is 6.

### Claim 27 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is C11 alkyl.

### Claim 28 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is alkenyl.

### Claim 29 (depends on 1)

The modified polypeptide of claim 1, wherein x is 3.

### Claim 30 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is C8 alkenyl.

### Claim 31 (depends on 1)

The modified polypeptide of claim 1, wherein x is 6.

### Claim 32 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is C11 alkenyl.

### Claim 33 (depends on 1)

The modified polypeptide of claim 1, wherein R3 is a straight chain alkyl, alkenyl, or alkynyl.

### Claim at position 31

-39. (canceled)

### Claim 40 (depends on 1)

The modified polypeptide of claim 1, further comprising a copolymer of lactic and glycolic acid

### Claim 41 (depends on 1)

The modified polypeptide of claim 1, further comprising an amino-terminal fatty acid.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The modified polypeptide of claim 1, further comprising a biotin moiety.

### Claim 44

A compound having the formula:
R1 is the side chain of any amino acid other than Gln;
R2 is —CH2OH [S];
R3 is —CH2CH2C(O)NH2 [Q]
R4 is the side chain of any amino acid other than Glu or Asp;
R5 is —C(OH)CH3 [T];
R6 is benzyl [F]
R7 and R14 together are Rx;
R8 is R4 is the side chain of any amino acid other than Glu or Asp;
R9 is —CH2CH(CH3)2 [L];
R10 is;
R11 is the side chain of any amino acid other than Lys;
R12 and R13 are —CH2CH(CH3)2 [L];
R15 is —CH2CH2C(O)NH2 [Q]; and
R16 is —CH2C(O)NH2 [N].
Rx is alkyl, alkenyl, alkynyl; [Rx1—K—Rx1]n; each of which is substituted with 0-6 Rx2;
Rx1 and Rx1′ are independently alkyl, alkenyl, or alkynyl;
Rx2 is halo, alkyl, ORx3, N(Rx3)2, SRx3, SORx3, SO2Rx3, CO2Rx3, Rx3, a fluorescent moiety, or a radioisotope;
K is O, S, SO, SO2, CO, CO2, CONRx3, or
R13 is H, alkyl or a therapeutic agent; and
Rz and Rw are independently: H, hydroxyl, amide (NH2), an amino acid, 2 to 10 amino acids linked by peptide bonds; tat; and PEG.

### Claim at position 37

45-58. (canceled)

### Claim 59 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide is transported through the cell membrane.

### Claim 60

A modified polypeptide of Formula (II),
or a pharmaceutically acceptable salt thereof,
wherein;
each R1 and R2 are independently H or a C1 to C10 alkyl, alkenyl, alkynyl, arylalkyl, cycloalkylalkyl, heteroarylalkyl, or heterocyclylalkyl;
R3 is alkylene, alkenylene or alkynylene, or [R4′-K-R4]n; each of which is substituted with 0-6 R5;
R4 and R4′ are independently alkylene, alkenylene or alkynylene (e.g., each are independently a C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10 alkylene, alkenylene or alkynylene);
R5 is halo, alkyl, OR6, N(R6)2, SR6, SOR6, SO2R6, CO2R6, R6, a fluorescent moiety, or a radioisotope;
K is O, S, SO, SO2, CO, CO2, CONR6, or
aziridine, episulfide, diol, amino alcohol;
R6 is H, alkyl, or a therapeutic agent;
n is 2, 3, 4 or 6;
x is an integer from 2-10;
w and y are independently an integer from 0-100;
z is an integer from 1-10 (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10); and
each Xaa is independently an amino acid (e.g., one of the 20 naturally occurring amino acids or any naturally occurring non-naturally occurring amino acid);
R7 is PEG, a tat protein, an affinity label, a targeting moiety, a fatty acid-derived acyl group, a biotin moiety, a fluorescent probe (e.g. fluorescein or rhodamine) linked via, e.g., a thiocarbamate or carbamate linkage;
R8 is H, OH, NH2, NHR8a, NR8aR8b;
wherein the polypeptide comprises at least 8 contiguous amino acids of SEQ ID NO:1 (human p53) or a variant thereof, SEQ ID NO:2 or a variant thereof, or another polypeptide sequence described herein except that: (a) within the 8 contiguous amino acids of SEQ ID NO:1 the side chains of at least one pair of amino acids separated by 3, 4 or 6 amino acids is replaced by the linking group, R3, which connects the alpha carbons of the pair of amino acids as depicted in formula I; and (b) the alpha carbon of the first of the pair of amino acids is substituted with R1 as depicted in Formula II and the alpha carbon of the second of the pair of amino acids is substituted with R2 as depicted in Formula II.
